Repeat Xena linked pub. PDD trail and use of Actigraph may end up being significant value added device. If the device works as advertised in this trial (in addition to typical sleep measures) then it all fits well with the Precision Medicine initiative and our recent Consortium of WW leaders.
https://www.ncbi.nlm.nih.gov/pubmed/24218292 IMO, it is also worth noting that such new equipment in use in any trial will tell one what is NOT and issue.In other words, if there was any debate that sleep was NOT and indicator of consequence then ERP data closes the point w/solid quantitative data. And, these kinds of trials are reproducible. Try that w/a survey.